Pharmaceutical Products
We strive to address unmet medical needs through excellence in science
:quality(90)/)
At Roche Pharmaceuticals, we focus on finding new medicines that help patients live longer, better lives and evolve the practice of medicine.
Below is a list of Roche medicines that are available in Aotearoa New Zealand. Use the filter function to filter by disease area to find the Data Sheet and Consumer Medicine Information (CMI) for each product.
If you have a question about a Roche medicine, please Contact Us.
For more information about Roche's Medicines and Cost Share Programmes, Healthcare Professionals can sign up on RocheHUB HCP Portal
Medsafe Registered Uses of Actemra (tocilizumab) Infusion:
Treatment of moderate to severe rheumatoid arthritis in adults, as well as certain types of systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis and certain patients with COVID-19.
Pharmac Funding Status of Actemra (tocilizumab) Infusion:
Funded Moderate to severe rheumatoid arthritis in adults
Funded Certain types of systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis
Funded Certain patients with COVID-19
See Pharmac websitefor more information.
If you would like to learn more about Actemra (tocilizumab) Infusion, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Actemra (tocilizumab) SC (subcutaneous injection):
Treatment of moderate to severe rheumatoid arthritis and giant cell arteritis in adults
Pharmac Funding Status of Actemra (tocilizumab) SC (subcutaneous injection):
Not Funded Moderate to severe rheumatoid arthritis in adults
Not Funded Giant cell arteritis in adults
Actemra (tocilizumab) SC (subcutaneous injection) is not publicly funded by PHARMAC, which means New Zealand patients are required to pay for this medication themselves.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about Actemra SC, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Alecensa (alectinib hydrochloride)
Treatment of locally advanced or metastatic ALK-positive non-small cell lung cancer.
Pharmac Funding Status of Alecensa (alectinib hydrochloride)
Funded Locally advanced or metastatic ALK-positive non-small cell lung cancer
See Pharmac webisitefor more information.
If you would like to learn more about Alecensa (alectinib hydrochloride), make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Avastin (bevacizumab)
Treatment of advanced (metastatic) bowel, kidney, breast, brain, lung, ovarian and cervical cancers
Pharmac Funding Status of Avastin (bevacizumab)
Not Funded Metastatic bowel cancer
Not Funded Metastatic kidney cancer
Not Funded Metastatic breast cancer
Not Funded Metastatic brain cancer
Not Funded Metastatic lung cancer
Not Funded Metastatic ovarian cancer
Not Funded Metastatic cervical cancer
Avastin (bevacizumab) is not publicly funded by PHARMAC, which means New Zealand patients are required to pay for this medication themselves.
To help New Zealand patients access this medicine, we have developed a number of cost share programmes which are designed to reduce the cost to patients. These programmes offer assistance with the cost of your medicine and often involve a cap being placed on either the number of doses or ‘cycles’ of the medicine, or the overall cost you pay. Your doctor can provide you with further information regarding the criteria for enrolling into one of the Roche Cost Share Programmes.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about Avastin (bevacizumab), make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of CellCept (mycophenolate mofetil)
Treatment to prevent rejection of transplanted organs
Pharmac Funding Status of CellCept (mycophenolate mofetil)
Funded To prevent rejection of transplanted organs
See Pharmac websitefor more information.
If you would like to learn more about CellCept (mycophenolate mofetil), make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Columvi (glofitamab)
Columvi in combination with gemcitabine and oxaliplatin is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) who are not candidates for autologous stem cell transplant (ASCT).
Columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.
Pharmac Funding Status of Columvi (glofitamab)
Columvi (glofitamab ) isn’t funded by PHARMAC. This means that you will need to pay for it at a private treatment centre.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about Columvi, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Cotellic (cobimetinib)
Treatment of advanced (metastatic) melanoma
Pharmac Funding Status of Cotellic (cobimetinib)
Not Funded Metastatic melanoma
Cotellic (cobimetinib) is not publicly funded by PHARMAC, which means New Zealand patients are required to pay for this medication themselves.
To help New Zealand patients access this medicine, we have developed a number of cost share programmes which are designed to reduce the cost to patients.
These programmes offer assistance with the cost of your medicine and often involve a cap being placed on either the number of doses or ‘cycles’ of the medicine, or the overall cost you pay. Your doctor can provide you with further information regarding the criteria for enrolling into one of the Roche Cost Share Programmes.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about Cotellic (cobimetinib), make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Erivedge (vismodegib)
Treatment of advanced (metastatic) basal cell carcinoma
Pharmac Funding Status of Erivedge (vismodegib):
Not Funded Metastatic basal cell carcinoma
Erivedge (vismodegib) is not publicly funded by PHARMAC, which means New Zealand patients are required to pay for this medication themselves.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about Erivedge (vismodegib), make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Esbriet (pirfenidone)
Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Pharmac Funding Status of Esbriet (pirfenidone):
Funded Idiopathic Pulmonary Fibrosis (IPF)
See Pharmac websitefor more information.
If you would like to learn more about Esbriet (pirfenidone), make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Evrysdi (risdiplam)
Treatment of spinal muscular atrophy (SMA) in patients aged 2 months and older.
Pharmac Funding Status of Evrysdi (risdiplam):
Funded Spinal Muscular Atrophy 18 years old and under
Not Funded Spinal Muscular Atrophy over 18 years old
See Pharmac websitefor more information.
Evrysdi (risdiplam) is not publicly funded by PHARMAC for all indications, which means some New Zealand patients are required to pay for this medication themselves.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about Evrysdi (risdiplam), make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Gazyva (obinutuzumab)
Treatment of previously untreated chronic lymphocytic leukaemia (CLL) and indolent non hodgkin lymphoma (iNHL)
Pharmac Funding Status of Gazyva (obinutuzumab):
Funded Previously untreated chronic lymphocytic leukaemia (CLL)
Funded Indolent non hodgkin lymphoma (iNHL)
See Pharmac websitefor more information.
If you would like to learn more about Gazyva (obinutuzumab), make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Hemlibra (emicizumab)
Treatment of congenital haemophilia A with or without factor VIII inhibitors
Pharmac Funding Status of Hemlibra (emicizumab):
Funded Congenital haemophilia A with factor VIII inhibitors
Funded Congenital haemophilia A without factor VIII inhibitors
See Pharmac websitefor more information.
If you would like to learn more about Hemlibra (emicizumab), make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Herceptin (trastuzumab) SC (subcutaneous injection)
Treatment of HER2-positive early and metastatic breast cancer
Pharmac Funding Status of Herceptin (trastuzumab) SC (subcutaneous injection):
Not Funded HER2-positive early and metastatic breast cancer
Herceptin (trastuzumab) SC (subcutaneous injection) is not publicly funded by PHARMAC, which means New Zealand patients are required to pay for this medication themselves.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about Herceptin (trastuzumab) SC (subcutaneous injection), make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Herceptin (trastuzumab) IV
Treatment of HER2-positive early and metastatic breast cancer and for HER2-positive advanced gastric cancer.
Pharmac Funding Status of Herceptin (trastuzumab) IV:
Not Funded HER2-positive early and metastatic breast cancer
Not Funded HER2-positive early and metastatic breast cancer
Herceptin (trastuzumab) IV is not publicly funded by PHARMAC, which means New Zealand patients are required to pay for this medication themselves.
To help New Zealand patients access this medicine, we have developed a number of cost share programmes which are designed to reduce the cost to patients.
These programmes offer assistance with the cost of your medicine and often involve a cap being placed on either the number of doses or ‘cycles’ of the medicine, or the overall cost you pay. Your doctor can provide you with further information regarding the criteria for enrolling into one of the Roche Cost Share Programmes.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about Herceptin (trastuzumab) IV, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Kadcyla (trastuzumab emtansine)
For the second-line treatment of HER2-positive metastatic breast cancer and adjuvant treatment in early HER2-positive breast cancer.
Pharmac Funding Status of Kadcyla (trastuzumab emtansine):
Funded Second-line treatment of HER2-positive metastatic breast cancer
Funded Adjuvant treatment in early HER2-positive breast cancer
See Pharmac websitefor more information.
If you would like to learn more about Kadcyla (trastuzumab emtansine), make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Mabthera RA (rituximab)
Treatment of rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis
Pharmac Funding Status of Mabthera RA (rituximab):
Funded Rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis
See Pharmac websitefor more information.
If you would like to learn more about Mabthera RA (rituximab), make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Madopar (levodopa and benserazide)
Treatment of Parkinson’s disease
Pharmac Funding status of Madopar (levodopa and benserazide):
Funded Parkinson's Disease
See Pharmac websitefor more information.
If you would like to learn more about Madopar (levodopa and benserazide), make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of NeoRecormon (epoetin beta)
Treatment of anaemia
Pharmac Funding Status of NeoRecormon (epoetin beta):
Not Funded Anaemia
NeoRecormon (epoetin beta) is not publicly funded by PHARMAC, which means New Zealand patients are required to pay for this medication themselves.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about NeoRecormon (epoetin beta), make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Ocrevus IV (ocrelizumab) and Ocrevus SC (ocrelizumab subcutaneous)
Treatment of relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS)
Pharmac Funding Status of Ocrevus IV (ocrelizumab):
Funded Relapsing Forms of Multiple Sclerosis (for patients who meet defined criteria)
Funded Primary Progressive Multiple Sclerosis (for patients who meet defined criteria)
Pharmac Funding Status of Ocrevus (ocrelizumab) SC (subcutaneous injection)
Not Funded for any indication
See Pharmac websitefor more information.
If you would like to learn more about Ocrevus IV (ocrelizumab) and Ocrevus SC (ocrelizumab subcutaneous), make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Perjeta (pertuzumab)
Treatment of HER2-positive early breast cancer either before or after surgery (neoadjuvant or adjuvant) and advanced (metastatic) breast cancer
Pharmac Funding Status of Perjeta (pertuzumab):
Not Funded HER2-positive early breast cancer either before or after surgery (neoadjuvant or adjuvant)
Funded Advanced (metastatic) breast cancer
See Pharmac websitefor more information.
Perjeta (pertuzumab) is not publicly funded by PHARMAC, which means some New Zealand patients are required to pay for this medication themselves.
To help New Zealand patients access this medicine, we have developed a number of cost share programmes which are designed to reduce the cost to patients.
These programmes offer assistance with the cost of your medicine and often involve a cap being placed on either the number of doses or ‘cycles’ of the medicine, or the overall cost you pay. Your doctor can provide you with further information regarding the criteria for enrolling into one of the Roche Cost Share Programmes.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about Perjeta (pertuzumab), make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Phesgo (trastuzumab+pertuzumab)
For the treatment of HER2-positive early breast cancer and HER-2 positive metastatic or locally recurrent unresectable breast cancer, in combination with chemotherapy.
Pharmac Funding Status of Phesgo (trastuzumab+pertuzumab):
Not Funded HER2-positive early breast cancer and HER-2 positive metastatic or locally recurrent unresectable breast cancer, in combination with chemotherapy
Phesgo (trastuzumab+pertuzumab) is not publicly funded by PHARMAC, which means New Zealand patients are required to pay for this medication themselves.
To help New Zealand patients access this medicine, we have developed a number of cost share programmes which are designed to reduce the cost to patients.
These programmes offer assistance with the cost of your medicine and often involve a cap being placed on either the number of doses or ‘cycles’ of the medicine, or the overall cost you pay. Your doctor can provide you with further information regarding the criteria for enrolling into one of the Roche Cost Share Programmes.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about Phesgo (trastuzumab+pertuzumab), make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Polivy (polatuzumab vedotin)
For the treatment of certain patients with diffuse large B-cell lymphoma
Pharmac Funding Status of Polivy (polatuzumab vedotin):
Not Funded Certain patients with diffuse large B-cell lymphoma
Polivy (polatuzumab vedotin) is not publicly funded by PHARMAC, which means New Zealand patients are required to pay for this medication themselves.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about Polivy (polatuzumab vedotin), make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Pulmozyme (dornase alfa)
Treatment of cystic fibrosis
Pharmac Funding Status of Pulmozyme (dornase alfa):
Funded Cystic fibrosis
See Pharmac websitefor more information.
If you would like to learn more about Pulmozyme (dornase alfa), make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of ROZLYTREK (entrectinib)
Treatment of ROS1 positive locally advanced and metastatic non-small cell lung cancer
Treatment of NTRK-fusion positive locally advanced and metastatic solid tumours
Pharmac Funding Status of ROZLYTREK (entrectinib):
Not Funded ROS1 positive locally advanced and metastatic non-small cell lung cancer
Not Funded Certain patients with NTRK fusion-positive locally advanced or metastatic solid tumours
ROZLYTREK (entrectinib) is not publicly funded by PHARMAC, which means New Zealand patients are required to pay for this medication themselves.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about ROZLYTREK (entrectinib), make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Tamiflu (oseltamivir)
Treatment of influenza
Pharmac Funding Status of Tamiflu (oseltamivir):
National Reserve Supply (to be released for use in pandemic setting)
If you would like to learn more about Tamiflu (oseltamivir), make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Tecentriq and Tecentriq SC
Treatment of early and metastatic non-small cell lung cancer, extensive-stage small cell lung cancer, metastatic urothelial carcinoma, unresectable hepatocellular carcinoma, and metastatic triple-negative breast cancer.
Pharmac Funding Status of Tecentriq
Funded Locally advanced or metastatic non-small cell lung cancer (NSCLC) who have previously received chemotherapy
Funded Hepatocellular carcinoma
Not Funded Urothelial cancer
Not Funded Triple negative breast cancer
Not Funded Other lung cancer indications
Pharmac Funding Status of Tecentriq SC
Not Funded for any indication
See Pharmac websitefor more information.
Tecentriq and Tecentriq SC are not publicly funded by PHARMAC for all indications, which means some New Zealand patients are required to pay for this medication themselves.
To help New Zealand patients access this medicine, we have developed a number of cost share programmes which are designed to reduce the cost to patients.
These programmes offer assistance with the cost of your medicine and often involve a cap being placed on either the number of doses or ‘cycles’ of the medicine, or the overall cost you pay. Your doctor can provide you with further information regarding the criteria for enrolling into one of the Roche Cost Share Programmes.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about Tecentriq and Tecentriq SC, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of VABYSMO (faricimab)
Treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and macular oedema secondary to retinal vein occlusion (RVO).
Pharmac Funding Status of VABYSMO (faricimab)
Not Funded Neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and macular oedema secondary to retinal vein occlusion (RVO).
VABYSMO (faricimab) is not publicly funded by PHARMAC, which means New Zealand patients are required to pay for this medication themselves.
To help New Zealand patients access this medicine, we have developed a number of cost share programmes which are designed to reduce the cost to patients.
These programmes offer assistance with the cost of your medicine and often involve a cap being placed on either the number of doses or ‘cycles’ of the medicine, or the overall cost you pay. Your doctor can provide you with further information regarding the criteria for enrolling into one of the Roche Cost Share Programmes.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about VABYSMO (faricimab), make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Zelboraf (vemurafenib)
Treatment of advanced (metastatic) melanoma.
Pharmac Funding Status of Zelboraf (vemurafenib)
Not Funded Advanced (metastatic) melanoma
Zelboraf (vemurafenib) is not publicly funded by PHARMAC, which means New Zealand patients are required to pay for this medication themselves.
To help New Zealand patients access this medicine, we have developed a number of cost share programmes which are designed to reduce the cost to patients.
These programmes offer assistance with the cost of your medicine and often involve a cap being placed on either the number of doses or ‘cycles’ of the medicine, or the overall cost you pay. Your doctor can provide you with further information regarding the criteria for enrolling into one of the Roche Cost Share Programmes.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about Zelboraf (vemurafenib), make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Actemra® (tocilizumab)
Uses of Actemra® (tocilizumab) Infusion:
Treatment of moderate to severe rheumatoid arthritis in adults, as well as certain types of systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis and certain patients with COVID-19.
More Information
Consumer Medicine Information
Data Sheet
Actemra® (tocilizumab) SC (subcutaneous injection)
Uses of Actemra® (tocilizumab) SC (subcutaneous injection):
Treatment of moderate to severe rheumatoid arthritis and giant cell arteritis in adults
More Information
Consumer Medicine Information (CMI)
Data Sheet
Mabthera RA® (rituximab)
Uses of Mabthera RA ® (rituximab):
Treatment of rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis
More Information
Consumer Medicine Information (CMI)
Data Sheet
Columvi® (glofitamab)
Uses of Columvi ® (glofitamab):
Columvi® has provisional consent. Columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.
More Information
Consumer Medicine Information
Data Sheet
Gazyva® (obinutuzumab)
Uses of Gazyva ® (obinutuzumab):
Treatment of previously untreated chronic lymphocytic leukaemia (CLL) and indolent non hodgkin lymphoma (iNHL)
More Information
Consumer Medicine Information (CMI)
Data Sheet
Learn more at Cancer Treatments
Hemlibra® (emicizumab)
Uses of Hemlibra ® (emicizumab):
Treatment of congenital haemophilia A with or without factor VIII inhibitors
More Information
Consumer Medicine Information (CMI)
Data Sheet
Learn more at www.hemlibra.co.nz
Polivy (polatuzumab vedotin)
Uses of Polivy (polatuzumab vedotin):
For the treatment of certain patients with diffuse large B-cell lymphoma
More Information
Consumer Information (CMI)
Data Sheet
VABYSMO® (faricimab)
Uses of VABYSMO® (faricimab):
Treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular oedema (DMO).
More Information
Consumer Medicine Information (CMI)
Data Sheet
Learn more at the VABYSMO website
Evrysdi® (risdiplam)
Uses of Evrysdi ® (risdiplam):
Treatment of spinal muscular atrophy (SMA) in patients aged 2 months and older.
More Information
Consumer Medicine Information (CMI)
Data Sheet
Madopar (levodopa and benserazide)
Uses of Madopar ® (levodopa and benserazide):
Treatment of Parkinson’s disease
More Information
Consumer Medicine Information (CMI)
Data Sheet
Ocrevus (ocrelizumab)
Uses of Ocrevus ® (ocrelizumab):
Treatment of relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS)
More Information
Consumer Medicine Information (CMI)
Data Sheet
Learn more at the Get On With Life website
Alecensa® (alectinib hydrochloride)
Uses of Alecensa® (alectinib hydrochloride):
Treatment of locally advanced or metastatic ALK-positive non-small cell lung cancer.
More Information
Consumer Medicine Information (CMI)
Data Sheet
Learn more at Cancer Treatments
Avastin® (bevacizumab)
Uses of Avastin® (bevacizumab):
Treatment of advanced (metastatic) bowel, kidney, breast, brain, lung, ovarian and cervical cancers
More Information
Consumer Medicine Information (CMI)
Data Sheet
Learn more at Cancer Treatments
Cotellic® (cobimetinib)
Uses of Cotellic® ® (cobimetinib):
Treatment of advanced (metastatic) melanoma
More Information
Consumer Medicine Information (CMI)
Data Sheet
Learn more at Cancer Treatments
Erivedge® (vismodegib)
Uses of Erivedge ® (vismodegib):
Treatment of advanced (metastatic) basal cell carcinoma
More Information
Consumer Medicine Information (CMI)
Data Sheet
Learn more at Cancer Treatments
Herceptin® (trastuzumab) SC (subcutaneous injection)
Uses of Herceptin ® (trastuzumab) SC (subcutaneous injection):
Treatment of HER2-positive early and metastatic breast cancer
More Information
Consumer Medicine Information (CMI)
Data Sheet
Herceptin® (trastuzumab) IV
Uses of Herceptin ® (trastuzumab) IV:
Treatment of HER2-positive early and metastatic breast cancer and for HER2-ve advanced gastric cancer.
More Information
Consumer Medicine Information (CMI)
Data Sheet
Kadcyla® (trastuzumab emtansine)
Uses of Kadcyla ® (trastuzumab emtansine):
For the second-line treatment of HER2-positive metastatic breast cancer and adjuvant treatment in early HER2-positive breast cancer.
More Information
Consumer Medicine Information (CMI)
Data Sheet
Learn more at Cancer Treatments
Perjeta® (pertuzumab)
Uses of Perjeta ® (pertuzumab):
Treatment of HER2-positive early breast cancer either before or after surgery (neoadjuvant or adjuvant) and advanced (metastatic) breast cancer
More Information
Consumer Medicine Information (CMI)
Data Sheet
Learn more at Cancer Treatments
Phesgo (trastuzumab+pertuzumab)
Uses of Phesgo (trastuzumab+pertuzumab):
For the treatment of HER2-positive early breast cancer and HER-2 positive metastatic or locally recurrent unresectable breast cancer, in combination with chemotherapy.
ROZLYTREK® (entrectinib)
Uses of ROZLYTREK ® (entrectinib):
Treatment of ROS1 positive locally advanced and metastatic non-small cell lung cancer
Treatment of NTRK-fusion positive locally advanced and metastatic solid tumours
More Information
Consumer Medicine Information (CMI)
Data Sheet
Learn more at Cancer Treatments
Tarceva® (erlotinib)
Uses of Tarceva ® (erlotinib):
Treatment of locally advanced or metastatic non-small cell lung cancer
More Information
Consumer Medicine Information (CMI)
Data Sheet
Learn more at Cancer Treatments
Tecentriq® (atezolizumab)
Uses of Tecentriq ® (atezolizumab):
Treatment of early and metastatic non-small cell lung cancer, extensive-stage small cell lung cancer, metastatic urothelial carcinoma, unresectable hepatocellular carcinoma, and metastatic triple-negative breast cancer.
More Information
Consumer Medicine Information (CMI)
Data Sheet
Learn more at Cancer Treatments
Zelboraf® (vemurafenib)
Uses of Zelboraf ® (vemurafenib):
Treatment of advanced (metastatic) melanoma
More Information
Consumer Medicine Information (CMI)
Data Sheet
Learn more at Cancer Treatments
Esbriet® (pirfenidone)
Uses of Esbriet ® (pirfenidone):
Treatment of Idiopathic Pulmonary Fibrosis (IPF)
More Information
Consumer Medicine Information (CMI)
Data Sheet
NeoRecormon (epoetin beta)
Uses of NeoRecormon ® (epoetin beta):
Treatment of anaemia
More Information
Consumer Medicine Information (CMI)
Data Sheet
Pulmozyme® (dornase alfa)
Uses of Pulmozyme ® (dornase alfa):
Treatment of cystic fibrosis
More Information
Consumer Medicine Information (CMI)
Data Sheet
CellCept® (mycophenolate mofetil)
Uses of CellCept® (mycophenolate mofetil):
Treatment to prevent rejection of transplanted organs
More Information
Consumer Medicine Information (CMI)
Data Sheet
Tamiflu® (oseltamivir)
Uses of Tamiflu ® (oseltamivir):
Treatment of influenza
More Information
Consumer Medicine Information (CMI)
Data Sheet
Responsible Business
The promotion and sale of pharmaceutical and diagnostics products is highly regulated. Roche has a strong commitment to comply with all applicable laws, regulations and industry codes.
In New Zealand our business practices are regulated and guided by the following Acts and Codes.
Advertising Standards Authority Therapeutic and Health Advertising Code
The Medical Technology Association of New Zealand Code (MTANZ) Code of Practice.
Our Code of Conduct also guides our business practices.